Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of real-world data

Alexander Olkus[1,2], Aurelie Tomczak[2,3], Anne Katrin Berger[4,5], Conrad Rauber[1,2], Philip Puchas[1], Cyrill Wehling[1,2], Thomas Longerich[2,3], Arianeb Mehrabi[2,6], De-Hua Chang[2,7], Jakob Liermann[2,8], Sophia Schäfer[2,4,5,9], Jan Pfeiffenberger[1, 2], Dirk Jäger[2,4,5], Patrick Michl[1,2], Christoph Springfeld[2,4,5], Michael T. Dill[1,2,5,10]

[1] Department of Gastroenterology, Infectious Diseases and Intoxication, Heidelberg University Hospital, Heidelberg, Germany

[2] Liver Cancer Center Heidelberg, Heidelberg, Germany

[3] Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

[4] Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany

[5] National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany

[6] Department of General, Visceral & Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany

[7] Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany

[8] Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany

[9] Clinical Cancer Registry, Heidelberg University Hospital, Heidelberg, Germany

[10] German Cancer Research Center (DKFZ) Heidelberg, Research Group Experimental Hepatology, Inflammation and Cancer, Heidelberg, Germany

Corresponding author:
Michael T. Dill, MD PhD
Heidelberg University Hospital
Department of Gastroenterology, Infectious Diseases and Intoxication
Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
Tel.: +49 6221 56 34064
E-Mail: michael.dill@med.uni-heidelberg.de
ORCID: 0000-0002-1926-4204

Supplementary Table 1: Clinically relevant genetic alterations

Patient	TMB	gene	type of mutation
2	4.72	*IDH1*	activating mutation
2	4.72	*BAP1*	deletion mutation
8	3.91	*MSH6*	deletion mutation
8	3.91	*GLI1*	deletion mutation
8	3.91	*BAP1*	deletion mutation
9	4.71	*TP53*	deletion mutation
9	4.71	*MUTYH*	deletion mutation
9	4.71	*ARID2*	deletion mutation
12	n.a.	*ERBB3*	activating mutation
12	n.a.	*BRAF*	deletion mutation
13	5.49	*TP53*	deletion mutation
13	5.49	*ABL1*	deletion mutation
13	5.49	*RTN3::EWSR1*	fusion
14	10.16	*NRAS*	deletion mutation
14	10.16	*TP53*	deletion mutation
14	10.16	*SMAD4*	deletion mutation
14	10.16	*AR*	deletion mutation
15	3.13	*KRAS*	activating mutation
16	7.03	*KRAS*	activating mutation
16	7.03	*SMAD4*	deletion mutation
18	3.91	*ARAF*	activating mutation
18	3.91	*BAP1*	deletion mutation
18	3.91	*LRP1B*	deletion mutation
20	3.91	*BAP1*	deletion mutation
20	3.91	*RANBP2*	deletion mutation
20	3.91	*FGFR2::NEK9*	fusion
34	0.00	*RET*	deletion mutation
34	0.00	*FGFR2:KCNH7*	fusion